NEUROCRINE BIOSCIENCES INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-12-31 was 92.00K shares, a 73.94% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-09-30 was 300.00K shares, a 50.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-06-30 was 500.00K shares, a 0.00% change year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-03-31 was 700.00K shares, a 133.33% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.50M shares, a 11.76% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.70M shares, a 112.50% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 800.00K shares, a 14.29% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 700.00K shares, a 0.00% change from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 1.50M shares 10-K · filed 2026-02-11 | |
| 2024-12-31 | 1.70M shares 10-K · filed 2025-02-10 | |
| 2023-12-31 | 800.00K shares 10-K · filed 2024-02-09 | |
| 2022-12-31 | 700.00K shares 10-K · filed 2023-02-09 | |
| 2021-12-31 | 700.00K shares 10-K · filed 2022-02-11 | |
| 2020-12-31 | 600.00K shares 10-K · filed 2021-02-05 | |
| 2019-12-31 | 983.00K shares 10-K · filed 2020-02-07 | |
| 2018-12-31 | 92.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | 1.59M shares 10-K · filed 2020-02-07 |
| 2018-09-30 | 300.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 1.85M shares derived: sum of 4 quarters · filed 2020-02-07 |
| 2018-06-30 | 500.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | 1.75M shares derived: sum of 4 quarters · filed 2020-02-07 |
| 2018-03-31 | 700.00K shares 10-Q · filed 2018-04-30 | 1.75M shares derived: sum of 4 quarters · filed 2020-02-07 |
| 2017-12-31 | 353.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | 1.35M shares 10-K · filed 2020-02-07 |
| 2017-09-30 | 200.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 1.04M shares derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-06-30 | 500.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | 941.00K shares derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-03-31 | 300.00K shares 10-Q · filed 2018-04-30 | 615.00K shares derived: sum of 4 quarters · filed 2019-02-08 |
| 2016-12-31 | 41.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | 341.00K shares 10-K · filed 2019-02-08 |
| 2016-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | 415.00K shares derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | 174.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | 415.00K shares derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | 26.00K shares 10-Q · filed 2017-05-09 | 641.00K shares derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | 115.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | 1.31M shares 10-K · filed 2018-02-13 |
| 2015-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | 1.74M shares derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | 400.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | 1.74M shares derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | 700.00K shares 10-Q · filed 2016-05-05 | 1.44M shares derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | 535.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | 1.14M shares 10-K · filed 2017-02-14 |
| 2014-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | 604.00K shares derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | 100.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | 804.00K shares derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | 400.00K shares 10-Q · filed 2015-04-30 | 1.00M shares derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | 4.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | 904.00K shares 10-K · filed 2016-02-11 |
| 2013-09-30 | 300.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | 1.01M shares derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-06-30 | 300.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | 709.00K shares derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-03-31 | 300.00K shares 10-Q · filed 2014-05-01 | 415.00K shares derived: sum of 4 quarters · filed 2015-02-09 |
| 2012-12-31 | 109.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | 209.00K shares 10-K · filed 2015-02-09 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | 109.00K shares derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | 6.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | 126.00K shares derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | 94.00K shares 10-Q · filed 2013-05-02 | |
| 2011-12-31 | 9.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | 94.00K shares 10-K · filed 2014-02-11 |
| 2011-09-30 | 17.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | |
| 2010-12-31 | 42.00K shares 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |